Oak Hill Bio

Oak Hill Bio

Phase 2
London, United KingdomFounded 2021oakhillbio.com

Oak Hill Bio Ltd is a clinical-stage biotechnology company focused on acquiring and developing life-changing rare disease therapeutics. The company’s pipeline includes three programs in late-stage clinical development – potential treatments for Angelman syndrome and complications of extremely premature birth – as well as a preclinical program for diabetic macular edema. Oak Hill has operations in the United States and the United Kingdom.

Founded
2021
Focus
Small Molecules

About

Oak Hill Bio Ltd is a clinical-stage biotechnology company focused on acquiring and developing life-changing rare disease therapeutics. The company’s pipeline includes three programs in late-stage clinical development – potential treatments for Angelman syndrome and complications of extremely premature birth – as well as a preclinical program for diabetic macular edema. Oak Hill has operations in the United States and the United Kingdom.

Funding History

2

Total raised: $57M

Series A$47MSofinnova PartnersJan 15, 2022
Seed$10MSofinnova PartnersJun 15, 2020

Company Info

TypePrivate
Founded2021
LocationLondon, United Kingdom
StagePhase 2
SIMILAR COMPANIES
Abbexa
Abbexa
Pre-clinical · Cambridge
Accentus Medical
Accentus Medical
Pre-clinical · Oxford
AbOliGo
AbOliGo
Pre-clinical · London
Bigespas
Bigespas
Pre-clinical · London
Actimed Therapeutics
Actimed Therapeutics
Pre-clinical · London
Is this your company?

Claim your profile to update information, add pipeline data, and connect with investors.

Claim profile